Trials / Completed
CompletedNCT02118714
Atrasentan Spermatogenesis and Testicular Function
A Multicenter, Single-Arm Study of the Effects of Atrasentan on Spermatogenesis and Testicular Function
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- Male
- Age
- 30 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is being conducted to evaluate the effects of Atrasentan on sperm production and testicular function in male subjects with Type 1 or 2 Diabetes and Nephropathy. This study included 2 periods: a Treatment Period (up to 26 weeks) followed by an Observational Period (up to an additional 52 weeks).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atrasentan | Atrasentan |
Timeline
- Start date
- 2015-04-06
- Primary completion
- 2018-04-18
- Completion
- 2018-07-16
- First posted
- 2014-04-21
- Last updated
- 2019-05-07
- Results posted
- 2019-05-07
Locations
13 sites across 4 countries: United States, Germany, Italy, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02118714. Inclusion in this directory is not an endorsement.